Agenus Inc reports results for the quarter ended June 30 - Earnings Summary

• Agenus Inc AGEN.OQ reported a quarterly adjusted loss of 100 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-2.52. The mean expectation of four analysts for the quarter was for earnings of $1.35 per share. Wall Street expected results to range from -78 cents to $2.87 per share.

• Revenue rose 9.3% to $25.69 million from a year ago; analysts expected $49.71 million.

• Agenus Inc shares had risen by 5.0% this quarter and gained 75.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 215.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Agenus Inc is $7.50, about 36% above its last closing price of $4.80

This summary was machine generated from LSEG data August 11 at 09:21 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)